10 US Pharma Stocks To Buy & Hold During COVID-19

Why is it a Good time to Invest in Pharma stocks?

Pharma Stocks

Pharma Stocks

The second wave of the COVID-19 pandemic has re-ignited the surge of the pharmaceutical industry, expeditiously.  Needless to say, the second wave of the viral epidemic has accelerated contamination that has resulted in crowd inflation in hospitals and clinic. In such a situation, the rise in demand for Pharma Stocks is inevitable.

Pharmaceutical stocks that lagged from profit margins and heavy revenues, shot up by 2021. The returns on investments (ROI) and revenues of the pharmaceuticals surpassed every other sector.

Hence, it can confidently be asserted that now is a good time to invest in pharma stocks.


The 10 Best Pharma Stocks To invest in 2021

Amneal Pharmaceuticals Inc.

Amenal specializes in the development and manufacture of generic and biosimilar pharmaceutical products. While the company faced a downfall in 2020 Q4 to $30 million. The sum rose by 28.4% year-over-year.

Amneal experiments with its products. This is one of the major factors that drive boosts in revenues.


Endo International PLC

Based in Ireland, Endo International PLC specializes in producing generic and branded drugs. Endo’s portfolio involves treatments for urology, orthopedic, endocrinology, and pain management.

One of the primary factors to invest in Endo International PLC is that the generic division of this pharmaceutical company blankets 135 product families and the company also is a seller of sterile injectable on a global basis.


Sanofi S.A.

Sanofi, a pharmaceutical company based in France, owns pharmaceutical, vaccines, and consumer health businesses. Sanofi’s products are famous for treating a wide range of complex diseases such as rheumatoid, diabetes, cardiovascular diseases, and cancer.

Given the fact that Sanofi produces vaccines that deal with complicated disorders, the products can then be used as antidotes to COVID-19 complications.



PPD is famously recognized as a contract research organization that specializes in providing development services to pharmaceuticals, biotechnology, medical device, and government organizations to speed up the production of drugs and vaccines.

The company’s earnings revenue increased by 30.3% year-over-year.  PPD is known to boost efficiency in drug making which is the need of the hour for the healthcare sector.


Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals is known to produce a range of products that treat muscle diseases and cancer. Some of its productions are namely, Ryanodex, Bendeka, and Belrapzo.

In 2020, Eagle’s net income $8.1 million. The earning was boosted by the second wave when there is an overwhelming demand for vaccines and drugs in healthcare institutions.


Emergent Bio Solutions

Emergent bio solutions specialize in products like anthrax vaccine, NARCAN nasal spray, and smallpox vaccines. Emergent witnessed a rise in revenue by 61.8% year-over-year.  Predictions are that its revenue will be ascending as the demands for the types of products it produces are rising amongst medical practitioners.


Mountain Valley MD Holdings Inc

Mountain Valley is a biochemical company based in Vancouver that produces drugs and vaccines aimed at pain management, weight loss, focus issues, anxiety. Mountain Valley has the maximum momentum that is witnessing a surge in its revenues.


Zomedica Corp

Zomedica is a well known veterinary company that directs its services towards animals. It focuses on detecting complex disorders in dogs and cats, especially the thyroid. Zomedica secured maximum revenues and profit by the March of 2021 after facing compliance issues with NYSE.



Abbvie in 2021, is boasting an impressive revenue gain. The revenue number in 2021 has surpassed the number in 2019. The digits of earnings stood at $7.9 billion. This number is now getting doubled in the current year 2021.

Abbvie’s portfolio includes fast-selling drugs and fast-growing products including cancer drugs.


Johnson and Johnson

Johnson and Johnson faced a downfall from 2018-2019. However, the revenue of the company is escalating as the second wave hit. It has witnessed a boost of around 35% in 2021.


Must see news